A three-year research program led by faculty at MIT aims to design the world’s first fully integrated, continuous mRNA manufacturing platform, in an $82 million effort funded by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. The resulting pilot-scale system is intended to improve society’s ability to respond to future pandemics as well as accelerate the development and production of mRNA technologies, which companies are investing in at unprecedented scales in hopes of developing new vaccines as well as new treatments to cancers, metabolic disorders,…
